2. Disease Areas
  3. Cancer Digestive System Disease
  4. Gastric Cancer Digestive System Cancer
  5. HER2-Positive Gastric Cancer

HER2-Positive Gastric Cancer

HER2-positive gastric cancer is characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor belonging to the EGFR family, which plays a critical role in regulating tumor cell proliferation, survival, adhesion, migration, and differentiation through downstream signaling pathways. While HER2 amplification or overexpression occurs across several cancers, it is most prominent in breast and gastric cancers, with an average global prevalence of 17.9% in gastric cancer and 8.8% among Chinese patients. Similar to HER2-positive breast cancer, this subtype is associated with more aggressive disease behavior and higher risk of metastasis. The development and clinical approval of trastuzumab, a targeted therapy against HER2, have significantly improved outcomes for patients with early-stage HER2-positive gastric cancer, establishing it as a standard treatment option.

HER2-Positive Gastric Cancer (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163099
    P5(PEG24)-VC-PAB-Exatecan 2928571-43-9 99.74%
    P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers.
    P5(PEG24)-VC-PAB-Exatecan
  • HY-N1073
    Wighteone 51225-30-0 98.71%
    Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFRL858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFRL858R/T790M mutation, and fungal infections.
    Wighteone
  • HY-P991149
    Nesfrotamig 2966936-23-0 99.22%
    Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors.
    Nesfrotamig